ACVRL1 and pulmonary arterial hypertension: Disruption of the SMAD1/5/8 pathway and BMP signalling, as a consequence of a BMPR2 or ACVRL1 mutation, results in inhibition of apoptosis of SMC leading to SMC proliferation and vascular remodelling, ultimately causing PAH [32,33,34].